Christopher K. Breuer, MD (Nationwide Children’s Hospital Research Inst.
The Ohio State University College of Medicine)
Karen Christman, PhD (University of California, San Diego)
Jennifer Elisseeff, PhD
(Johns Hopkins University)
Kirk Hansen, PhD (University of Colorado, Anschutz Medical Campus)
Jeffrey Hubbell, PhD (The University of Chicago)
Alberto Mantovani, MD
Robert Mecham, PhD (Washington University in St. Louis)
Laura Niklason, PhD, MD
Harald Ott, MD
Katja Schenke-Layland, PhD, MSc
(Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB))
Molly Stevens, PhD
(Imperial College London)
Valerie Weaver, PhD
(University of California, San Francisco)
This symposium is designed to advance the use of biologic scaffold materials for regenerative medicine and all general surgery applications. The format includes a series of presentations describing the potential benefits and risks associated with the use of such materials, factors that affect performance, and the clinical applications that may benefit most from their use. Topics range from the most basic science of cell:matrix interaction, and mechanisms of scaffold remodeling at the molecular level through the preclinical and clinical level. It is not the intent of this symposium to discuss only the beneficial aspects of biologic scaffolds, but just as importantly to identify the problem areas, develop strategies for solving these problems, and initiate collaborations among basic scientists and clinicians in attendance at the meeting. Our feedback from previous symposia (this is a bi-annual event) consistently identifies the equal mix of clinicians and basic scientists as the most beneficial and rewarding aspect of the meeting.
CALL FOR ABSTRACTS and SYMPOSIUM TOPICS
Abstracts will be considered for all topics related to the use of biologic scaffolds for tissue engineering/regenerative medicine including: fundamental concepts of cell-scaffold interactions, tissue source and processing/manufacturing methods, whole organ engineering with biologic scaffolds, pre-clinical studies of tissue and organ reconstruction, factors that influence the host remodeling response, and results/outcomes of human clinical applications. It is anticipated that approximately 50% of the abstracts accepted for podium presentation will relate to human clinical experiences in body systems that include cardiovascular, gastrointestinal, urologic, dermatologic, musculoskeletal, and the central nervous system. The remaining 50% will relate to basic science and mechanistic concepts. Abstracts will be considered for podium presentation and poster session display. Abstracts will be accepted beginning August 15, 2017 and will close on December 1, 2017. Notifications will be sent by January 5, 2018.
Abstracts should be no longer than 3000 characters, (approximately) 500 words, and fit on 1 page.
Use Arial typeface, a black font color, and a font size of 11 points or larger. A Symbol font may be used to insert Greek letters or special characters. Use at least one-half inch margins (top, bottom, left, and right) for all pages.
Author’s names should be displayed using full first and last names. Presenting author’s name should be bolded and underlined.
The abstract should clearly describe the nature of the research and be presented in such language as to be understood by both scientists and clinicians. The abstract should clearly identify the objectives of the research, the methodology employed, the results, and conclusions.